[A25-107] Belzutifan (renal cell carcinoma) – Addendum to Project A25-45
Last updated 18.09.2025
Project no.:
A25-107
Commission:
Commission awarded on 12.08.2025 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adult patients with advanced clear cell renal cell carcinoma that has progressed following 2 or more lines of therapy that included a PD‑(L)1 inhibitor and at least 2 vascular endothelial growth factor‑targeted therapies
- Patients < 65 years of age for whom everolimus is a suitable individualized treatment: unchanged after addendum: hint of a minor added benefit
- Patients ≥ 65 years of age for whom everolimus is a suitable individualized treatment: unchanged after addendum: hint of a considerable added benefit
- Patients for whom everolimus is not a suitable individualized treatment: unchanged after addendum: added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently relevant page on the extent of the added benefit, thus completing the early benefit assessment.
https://doi.org/10.60584/A25-107
| Project no. | Title | Status |
|---|---|---|
| A25-45 | Belzutifan (renal cell carcinoma) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2025-09-18 A G-BA decision was published.